LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST
The data from a range of large trials (LEADER, EMPA-REG, CANVAS) show evidently the practical use of the modern glucose lowering drugs usage for successful management of cardiovascular risk in type 2 diabetes (DM2) patients. The article is focused on analysis and review of possible mechanisms and be...
Main Author: | |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2018-05-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/2717 |
id |
doaj-1ff7874428e34be7a1b9f1eda46ddb76 |
---|---|
record_format |
Article |
spelling |
doaj-1ff7874428e34be7a1b9f1eda46ddb762021-07-28T14:02:32Zrus«FIRMA «SILICEA» LLC Российский кардиологический журнал1560-40712618-76202018-05-0104899210.15829/1560-4071-2018-4-89-922369LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNISTS. V. Nedogoda0Volgograd State Medical University of the Ministry of Health.The data from a range of large trials (LEADER, EMPA-REG, CANVAS) show evidently the practical use of the modern glucose lowering drugs usage for successful management of cardiovascular risk in type 2 diabetes (DM2) patients. The article is focused on analysis and review of possible mechanisms and benefits of cardiovascular risk reduction in DM2 with prescription of the antagonist of glucagonlike peptide 1 — liraglutide (Victoza®).https://russjcardiol.elpub.ru/jour/article/view/2717diabetescardiovascular riskliraglutideglucagon-like peptide 1adipokines |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
S. V. Nedogoda |
spellingShingle |
S. V. Nedogoda LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST Российский кардиологический журнал diabetes cardiovascular risk liraglutide glucagon-like peptide 1 adipokines |
author_facet |
S. V. Nedogoda |
author_sort |
S. V. Nedogoda |
title |
LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST |
title_short |
LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST |
title_full |
LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST |
title_fullStr |
LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST |
title_full_unstemmed |
LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES — A MANDATE FOR CARDIOLOGIST AND INTERNIST |
title_sort |
liraglutide pleiotropic effect in cardiovascular risk reduction in type 2 diabetes — a mandate for cardiologist and internist |
publisher |
«FIRMA «SILICEA» LLC |
series |
Российский кардиологический журнал |
issn |
1560-4071 2618-7620 |
publishDate |
2018-05-01 |
description |
The data from a range of large trials (LEADER, EMPA-REG, CANVAS) show evidently the practical use of the modern glucose lowering drugs usage for successful management of cardiovascular risk in type 2 diabetes (DM2) patients. The article is focused on analysis and review of possible mechanisms and benefits of cardiovascular risk reduction in DM2 with prescription of the antagonist of glucagonlike peptide 1 — liraglutide (Victoza®). |
topic |
diabetes cardiovascular risk liraglutide glucagon-like peptide 1 adipokines |
url |
https://russjcardiol.elpub.ru/jour/article/view/2717 |
work_keys_str_mv |
AT svnedogoda liraglutidepleiotropiceffectincardiovascularriskreductionintype2diabetesamandateforcardiologistandinternist |
_version_ |
1721269091774234624 |